Chemical structure of entacapone
Find information on thousands of medical conditions and prescription drugs.

Entacapone

Entacapone is a catechol-O-methyl transferase inhibitor, marketed by Novartis for the treatment of Parkinson's disease under the trade names Comtan and Stalevo in the United States. When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone increases the bioavailability of these compounds by facilitating their passage across the blood-brain barrier. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is a member of the class of nitrocatechols.

The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias).These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including diarrhoea, nausea and abdominal pains. The substance may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.

Read more at Wikipedia.org


[List your site here Free!]


Rx for Parkinson's - Brief Article - Statistical Data Included
From Family Pratice News, 1/15/00

Comtan (entacapone) is indicated to prolong the benefits of levodopa-carbidopa medications in patients with Parkinson's disease who have end-of-dose "wearing off." It belongs to the new therapeutic class of catechol-O-methyltransferase (COMT) inhibitors, which block the COMT enzyme and reduce breakdown of levodopa before it reaches the brain. The drug, which had a favorable side-effect profile in clinical trials, requires no special safety monitoring, according to Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936-1080, 888-644-8585.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Entacapone
Home Contact Resources Exchange Links ebay